Active substance
Griseofulvin
- SFDA 7
- US price lines 2
- NHS prices 2
- WHO EML 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| FULCIN 125 MG TAB | 125 mg | Tablet · Oral use | 100 Tablet Container | SAR 17.80 | NCE · Prescription | AstraZeneca | Withdrawn by MAH · Not Marketed |
| FULCIN SYRUP 125MG-5 ML. | 25 mg/ml | Syrup · Oral use | 1 Bottle | SAR 7.95 | NCE · Prescription | AstraZeneca | Withdrawn by MAH · Not Marketed |
| FULCIN TABLETS 500 MG. | 500 mg | Tablet · Oral use | 25 Blister | SAR 17.35 | NCE · Prescription | AstraZeneca | Withdrawn by MAH · Not Marketed |
| GRISOVIN TABLETS 125 MG. | 125 mg | Tablet · Oral use | 100 Tablet Container | SAR 16.20 | Generic · Prescription | GLAXO | Withdrawn by MAH · Not Marketed |
| GRISOVIN TABLETS 125 MG. | 125 mg | Tablet · Oral use | 25 Blister | SAR 4.05 | Generic · Prescription | GLAXO | Withdrawn by MAH · Not Marketed |
| GRISOVIN TABLETS 500 MG. | 500 mg | Tablet · Oral use | 25 Blister | SAR 15.95 | Generic · Prescription | GLAXO | Withdrawn by MAH · Not Marketed |
| GRISOVIN TABLETS 500 MG. | 500 mg | Tablet · Oral use | 100 Tablet Container | SAR 62.55 | Generic · Prescription | GLAXO | Withdrawn by MAH · Not Marketed |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | GRISEOFULVIN 125 MG/5 ML SUSP | $0.25215 | per ML | 23 Sep 2026 |
| US NADAC | GRISEOFULVIN 125 MG/5 ML SUSP | $0.39132 | per ML | 23 Sep 2026 |
| NHS Drug Tariff | Griseofulvin 125mg tablets | £121.80 | 100 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Griseofulvin 500mg tablets | £113.82 | 100 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 6.3. Antifungal medicines · core
Dermatophytosis
Oral > Liquid: 125 mg per 5 mL (EMLc) | Oral > Solid: 125 mg; 250 mg
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.